D
4.27
-0.51 (-10.67%)
| Previous Close | 4.78 |
| Open | 5.40 |
| Volume | 6,936,616 |
| Avg. Volume (3M) | 1,762,252 |
| Market Cap | 61,466,224 |
| Price / Sales | 2.26 |
| Price / Book | 1.80 |
| 52 Weeks Range | |
| Earnings Date | 31 Mar 2025 - 4 Apr 2025 |
| TTM Dividend Yield | 7.49% |
| Profit Margin | -180.22% |
| Operating Margin (TTM) | -79.05% |
| Diluted EPS (TTM) | -3.86 |
| Quarterly Revenue Growth (YOY) | 319.80% |
| Total Debt/Equity (MRQ) | 8.23% |
| Current Ratio (MRQ) | 8.69 |
| Operating Cash Flow (TTM) | -16.65 M |
| Levered Free Cash Flow (TTM) | -9.75 M |
| Return on Assets (TTM) | -42.55% |
| Return on Equity (TTM) | -46.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Dominari Holdings Inc. | - | - |
AIStockmoo Score
0.6
| Analyst Consensus | 0.0 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.60 |
|
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 53.16% |
| % Held by Institutions | 3.34% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HAYES ANTHONY | 5.49 | - | 154,559 | 848,529 |
| Aggregate Net Quantity | 154,559 | |||
| Aggregate Net Value ($) | 848,529 | |||
| Aggregate Avg. Buy ($) | 5.49 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HAYES ANTHONY | Officer | 24 Mar 2025 | Acquired (+) | 154,559 | 5.49 | 848,529 |
| TTM Dividend Yield | 7.49% |
| Expected Next Dividend Payment | Mar 2026 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 24 Feb 2025 | 10 Feb 2025 | 03 Mar 2025 | 0.32 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 0.320 | 1 | 7.49 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |